Aclaris Historical Income Statement

ACRS Stock

USD 4.32 0.36 9.09%

Historical analysis of Aclaris Therapeutics income statement accounts such as Interest Expense of 3.2 M, Selling General Administrative of 21.3 M or Other Operating Expenses of 77.2 M can show how well Aclaris Therapeutics performed in making a profits. Evaluating Aclaris Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Aclaris Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Aclaris Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aclaris Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

About Aclaris Income Statement Analysis

Aclaris Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Aclaris Therapeutics shareholders. The income statement also shows Aclaris investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Aclaris Therapeutics Income Statement Chart

At this time, Aclaris Therapeutics' Research Development is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 8.9 M in 2024, whereas Interest Expense is likely to drop slightly above 3.2 M in 2024.

Selling General Administrative Other Operating Expenses Operating Income Research Development Total Operating Expenses Gross Profit

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Aclaris Therapeutics. It is also known as Aclaris Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Aclaris Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Aclaris Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Aclaris Therapeutics minus its cost of goods sold. It is profit before Aclaris Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Aclaris Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Aclaris Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.At this time, Aclaris Therapeutics' Research Development is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 8.9 M in 2024, whereas Interest Expense is likely to drop slightly above 3.2 M in 2024.

Aclaris Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Net Income From Continuing Ops	Income Tax Expense	Interest Income	Non Operating Income Net Other	Discontinued Operations	Tax Provision	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses	Non Recurring
Depreciation And Amortization		0.3	0.27	-0.4	-0.36	0.24	-0.17	0.29	-0.41	-0.31	-0.52	-0.42	0.77	0.09	-0.52	-0.55	0.38	0.97	-0.34	-0.35	0.09
Selling General Administrative	0.3		0.91	-0.9	-0.9	0.82	-0.89	0.92	-0.91	0.41	-0.88	-0.9	0.32	-0.27	0.37	0.02	0.73	0.42	-0.73	-0.61	-0.27
Other Operating Expenses	0.27	0.91		-0.96	-0.96	0.87	-0.96	1.0	-0.95	0.49	-0.9	-0.95	0.28	-0.29	0.49	-0.1	0.82	0.43	-0.82	-0.58	-0.29
Operating Income	-0.4	-0.9	-0.96		0.99	-0.89	0.97	-0.97	0.99	-0.47	0.95	0.98	-0.36	0.39	-0.4	0.2	-0.81	-0.56	0.82	0.58	0.39
Ebit	-0.36	-0.9	-0.96	0.99		-0.93	0.98	-0.96	0.97	-0.55	0.93	0.97	-0.32	0.47	-0.44	0.14	-0.81	-0.53	0.82	0.6	0.47
Research Development	0.24	0.82	0.87	-0.89	-0.93		-0.93	0.86	-0.86	0.73	-0.81	-0.85	0.2	-0.68	0.54	0.17	0.77	0.39	-0.79	-0.74	-0.68
Ebitda	-0.17	-0.89	-0.96	0.97	0.98	-0.93		-0.96	0.94	-0.65	0.88	0.94	-0.18	0.51	-0.58	0.03	-0.77	-0.36	0.79	0.56	0.51
Total Operating Expenses	0.29	0.92	1.0	-0.97	-0.96	0.86	-0.96		-0.96	0.46	-0.92	-0.96	0.29	-0.27	0.47	-0.15	0.81	0.45	-0.81	-0.55	-0.27
Income Before Tax	-0.41	-0.91	-0.95	0.99	0.97	-0.86	0.94	-0.96		-0.38	0.99	1.0	-0.47	0.31	-0.31	0.18	-0.85	-0.57	0.85	0.61	0.31
Total Other Income Expense Net	-0.31	0.41	0.49	-0.47	-0.55	0.73	-0.65	0.46	-0.38		-0.26	-0.37	-0.41	-0.86	0.83	0.4	0.27	-0.19	-0.34	-0.33	-0.86
Net Income	-0.52	-0.88	-0.9	0.95	0.93	-0.81	0.88	-0.92	0.99	-0.26		0.99	-0.62	0.25	-0.16	0.21	-0.86	-0.66	0.85	0.65	0.25
Net Income From Continuing Ops	-0.42	-0.9	-0.95	0.98	0.97	-0.85	0.94	-0.96	1.0	-0.37	0.99		-0.48	0.31	-0.31	0.19	-0.86	-0.58	0.85	0.61	0.31
Income Tax Expense	0.77	0.32	0.28	-0.36	-0.32	0.2	-0.18	0.29	-0.47	-0.41	-0.62	-0.48		0.16	-0.62	-0.3	0.52	0.76	-0.47	-0.48	0.16
Interest Income	0.09	-0.27	-0.29	0.39	0.47	-0.68	0.51	-0.27	0.31	-0.86	0.25	0.31	0.16		-0.49	-0.39	-0.29	-0.03	0.35	0.45	1.0
Non Operating Income Net Other	-0.52	0.37	0.49	-0.4	-0.44	0.54	-0.58	0.47	-0.31	0.83	-0.16	-0.31	-0.62	-0.49		0.26	0.14	-0.41	-0.18	-0.03	-0.49
Discontinued Operations	-0.55	0.02	-0.1	0.2	0.14	0.17	0.03	-0.15	0.18	0.4	0.21	0.19	-0.3	-0.39	0.26		0.07	-0.55	-0.1	-0.44	-0.39
Tax Provision	0.38	0.73	0.82	-0.81	-0.81	0.77	-0.77	0.81	-0.85	0.27	-0.86	-0.86	0.52	-0.29	0.14	0.07		0.55	-1.0	-0.84	-0.29
Reconciled Depreciation	0.97	0.42	0.43	-0.56	-0.53	0.39	-0.36	0.45	-0.57	-0.19	-0.66	-0.58	0.76	-0.03	-0.41	-0.55	0.55		-0.53	-0.46	-0.03
Extraordinary Items	-0.34	-0.73	-0.82	0.82	0.82	-0.79	0.79	-0.81	0.85	-0.34	0.85	0.85	-0.47	0.35	-0.18	-0.1	-1.0	-0.53		0.85	0.35
Selling And Marketing Expenses	-0.35	-0.61	-0.58	0.58	0.6	-0.74	0.56	-0.55	0.61	-0.33	0.65	0.61	-0.48	0.45	-0.03	-0.44	-0.84	-0.46	0.85		0.45
Non Recurring	0.09	-0.27	-0.29	0.39	0.47	-0.68	0.51	-0.27	0.31	-0.86	0.25	0.31	0.16	1.0	-0.49	-0.39	-0.29	-0.03	0.35	0.45

Click cells to compare fundamentals

Aclaris Therapeutics Account Relationship Matchups

Aclaris Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	37.0M	1.3M	923K	797K	863K	819.9K
Selling General Administrative	27.2M	20.5M	23.6M	25.1M	31.1M	21.3M
Other Operating Expenses	96.8M	57.4M	72.1M	114.9M	128.6M	77.2M
Operating Income	(111.1M)	(50.9M)	(65.4M)	(85.2M)	(97.4M)	(102.2M)
Ebit	(111.1M)	(50.9M)	(66.0M)	(85.2M)	(118.4M)	(112.5M)
Research Development	64.9M	31.7M	43.8M	77.8M	98.4M	103.3M
Ebitda	(74.1M)	(49.6M)	(65.1M)	(84.4M)	(117.6M)	(111.7M)
Total Operating Expenses	92.7M	52.3M	67.4M	102.9M	110.5M	72.0M
Income Before Tax	(113.5M)	(51.3M)	(90.9M)	(86.9M)	(88.8M)	(93.3M)
Total Other Income Expense Net	(2.5M)	(424K)	(1.1M)	2.9M	8.5M	8.9M
Net Income	(142.9M)	(51.2M)	(114.3M)	(88.7M)	(88.5M)	(92.9M)
Total Revenue	4.2M	6.5M	6.8M	29.8M	31.2M	32.8M
Gross Profit	172K	1.3M	2.0M	17.8M	13.2M	13.8M
Net Income From Continuing Ops	(113.5M)	(51.2M)	(90.9M)	(86.9M)	(88.5M)	(92.9M)
Cost Of Revenue	4.1M	5.1M	4.7M	12.0M	18.1M	19.0M
Net Income Applicable To Common Shares	(161.4M)	(51.0M)	(90.9M)	(86.9M)	(78.2M)	(82.1M)
Income Tax Expense	29.3M	(182K)	23.4M	1.8M	(367K)	(348.7K)
Non Operating Income Net Other	(2.5M)	(424K)	(1.1M)	2.9M	2.7M	2.8M
Reconciled Depreciation	6.4M	1.3M	923K	797K	863K	1.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aclaris Historical Income Statement

About Aclaris Income Statement Analysis

Aclaris Therapeutics Income Statement Chart

Other Operating Expenses

Operating Income

Total Operating Expenses

Gross Profit

Aclaris Therapeutics income statement Correlations

Aclaris Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aclaris Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aclaris Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Other Operating Expenses
Operating Income	Ebit
Research Development	Ebitda
Total Operating Expenses	Income Before Tax
Total Other Income Expense Net	Net Income
Total Revenue	Gross Profit
Net Income From Continuing Ops	Cost Of Revenue
Net Income Applicable To Common Shares	Income Tax Expense
Interest Income	Preferred Stock And Other Adjustments
Non Operating Income Net Other	Discontinued Operations
Tax Provision	Reconciled Depreciation
Extraordinary Items	Selling And Marketing Expenses
Non Recurring

Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Income Before Tax
Non Recurring	+ 1.0	Interest Income
Ebit	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Operating Income
Net Income	+ 0.99	Income Before Tax

Extraordinary Items	- 1.0	Tax Provision
Total Operating Expenses	- 0.97	Operating Income
Net Income From Continuing Ops	- 0.96	Total Operating Expenses
Income Before Tax	- 0.96	Total Operating Expenses
Total Operating Expenses	- 0.96	Ebitda
Total Operating Expenses	- 0.96	Ebit